Cyclerion Therapeutics (KRSA) Set to Announce Earnings on Wednesday

Key Points

• Cyclerion is scheduled to report Q3 2026 results on Wednesday, November 11. Analysts forecast a loss of $50.40 per share and revenue of $0.55 million; the earnings call is scheduled for November 12 at 4:00 p.m. ET.
• Shares recently traded at $31.50, down $0.46 on the day, with a 52-week range of $7.19 to $59.36.
• Analyst opinion is mixed but leans positive: MarketBeat reports a Moderate Buy consensus and a $53 average price target, alongside ratings ranging from Strong Buy to Sell.

Cyclerion Therapeutics (NASDAQ:KRSA - Get Free Report) is expected to announce its Q3 2026 resultson Wednesday, November 11th. Analysts expect Cyclerion Therapeutics to post earnings of ($50.40) per share and revenue of $0.55 million for the quarter. Investors can find conference call details on the company's upcoming Q3 2026 earnings results page for the latest details on the call scheduled for Thursday, November 12, 2026 at 4:00 PM ET.

Cyclerion Therapeutics Stock Performance

NASDAQ KRSA traded down $0.46 during trading hours on Wednesday, reaching $31.50. 11,584 shares of the company were exchanged, compared to its average volume of 280,134. Cyclerion Therapeutics has a 1 year low of $7.19 and a 1 year high of $59.36. The company has a market capitalization of $1.43 billion, a PE ratio of -2.74 and a beta of 1.85.

Analyst Upgrades and Downgrades

Several research firms have recently weighed in on KRSA. UBS Group began coverage on shares of Cyclerion Therapeutics in a report on Friday, September 11th. They issued a "buy" rating and a $55.00 price target on the stock. Wedbush started coverage on Cyclerion Therapeutics in a report on Monday, October 5th. They issued an "outperform" rating and a $44.00 target price on the stock. Wall Street Zen raised Cyclerion Therapeutics to a "sell" rating in a report on Saturday, October 3rd. TD Cowen started coverage on Cyclerion Therapeutics in a research note on Monday, September 14th. They issued a "buy" rating for the company. Finally, Stifel Nicolaus initiated coverage on shares of Cyclerion Therapeutics in a report on Monday, September 14th. They issued a "buy" rating and a $43.00 target price for the company. One research analyst has rated the stock with a Strong Buy rating, four have assigned a Buy rating, one has given a Hold rating and one has assigned a Sell rating to the company. According to MarketBeat.com, the company presently has an average rating of "Moderate Buy" and a consensus target price of $53.00.

Cyclerion Therapeutics Company Profile

Cyclerion Therapeutics, Inc was a clinical-stage biopharmaceutical company focused on developing medicines for serious central nervous system and cardiopulmonary diseases. The company's research centered on soluble guanylate cyclase (sGC) stimulators, a class of compounds intended to regulate cellular signaling and potentially address diseases associated with impaired nitric oxide signaling.

Cyclerion was formed in 2019 as a spin-off from Ironwood Pharmaceuticals. Its historical development portfolio included olinciguat, an investigational treatment studied for sickle cell disease, and praliciguat, which was evaluated for conditions including diabetic nephropathy and nonalcoholic steatohepatitis.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.